Abstract

Cancer is a multifactorial disease that constitutes a serious public health problem worldwide. Prostate cancer advanced stages are associated with the development of androgen-independent tumors and an apoptosis-resistant phenotype that progresses to metastasis. By studying androgen-independent lymphoid nodule carcinoma of the prostate (LNCaP) cells induced to apoptosis by serum elimination, we identified the activation of a non-selective cationic channel of 23pS conductance that promotes incoming Ca\(^{2+}\) currents, as well as apoptosis final stages. arp2cDNA was isolated and identified to be of the same cell type, and mRNA was expressed in Xenopus laevis oocytes, which was found to be associated with the activation of incoming Ca\(^{2+}\) currents and induction to apoptosis. cDNA, which encodes the ARP2 protein, was overexpressed in LNCaP cells and Chinese hamster ovary cells, which induced apoptosis. Our evidence suggests that protein ARP2 overexpression and transit to the cell membrane allows an increased Ca\(^{2+}\) incoming current that initiates the apoptosis process in epithelial-type cells whose phenotype shows resistance to programmed cell death.

KEY WORDS: Apoptosis. ARP2 protein. Epithelial carcinoma. Prostate cancer.

Introduction

Cancer is a multifactorial disease and the second cause of death of general population in the world. Its causality is related to lifestyle, genetic predisposition and psychological and mood states of individuals. The prevalence of cancer has increased in recent years, and it is therefore a health problem that demands a very high level of attention. In males, the highest rates of cancer incidence occur in the prostate, lung, bronchi, colon, rectum and urinary bladder; in females, in the breast, lung, bronchi, colon, rectum, uterus and thyroid gland. The above is an indicator that the most common types of cancer in men and women, respectively, are prostate and breast cancer. In children, the highest incidence of cancer is observed in the bone marrow, brain and lymph nodes. Epithelial cancer is one of the most aggressive types. Particularly in prostate cancer, the treatment will depend on the stage the disease is identified at; however, it is very common for it to progress and develop a phenotype of apoptosis resistance and, therefore, of hormone independence, which makes for cells to continue proliferating until metastasis is reached, hence the development of new therapeutic strategies that prevent the disease from reaching advanced stages being essential.

During the process of apoptosis of numerous cell types, a sustained increase in cytoplasmic Ca\(^{2+}\) has been defined as a determinant in the onset of programmed cell death. Considering this rationale, for years we have worked on the study of the mechanisms of cytoplasmic calcium homeostasis control and the impact of Ca\(^{2+}\) altered level in various cell and neoplastic types.
We have been able to demonstrate that an increased level of cytoplasmic calcium results in the onset of programmed cell death in Chinese hamster epithelial cell lines of prostate and ovarian cancer. In this sense, our research group discovered a nonselective cationic channel permeable to Ca\(^{2+}\) with 23pS-conductance, expressed under conditions of induced apoptosis by removing serum from the culture medium in androgen-independent lymph node carcinoma of the prostate (LNCaP) cells.\(^8\) In addition, it was also possible to isolate the complementary DNA (cDNA) from LNCaP cells that encodes apoptosis regulatory protein 2 (which we called ARP2), which, when overexpressed, induces apoptosis in \textit{Xenopus laevis} oocytes and androgen-independent LNCaP cells, from which ARP2 was originally isolated.\(^9\) ARP2 overexpression was shown to induce Chinese hamster ovary cell apoptosis. These findings demonstrate that Ca\(^{2+}\) increased levels are an indispensable condition to initiate apoptosis in various epithelial cell lines, and this protein could therefore constitute an excellent tool in the future in the treatment of the disease by preventing progression to the advanced stages that culminate with a metastatic process.

**Prostate cancer**

Prostate cancer is the second leading cause of cancer-related death in the United States and the fifth in the world.\(^{10-12}\) The prevalence of this disease increases with increasing age. Prostate cancer is found during autopsy in more than half of men older than 50 years in the United States, in spite of this disease being the cause of death only in 3 %. It is an asymptomatic disease until the appearance of metastatic lesions that are usually discovered in bone tissue. Initial therapies for its treatment include surgery, radiation, and use of 5-alpha reductase inhibitors, which promotes the formation of more potent androgens from testosterone.\(^{13}\) Initial treatment methods often cause sexual, urinary and intestinal dysfunction.\(^{14}\)

From the molecular point of view, this disease manifests itself at early and late stages. In the former, prostate cell proliferation is slow and dependent on androgens, so that during treatment with chemotherapeutic agents, the cells manage to repair the damage and continue to proliferate. Over time, cells become independent of androgenic hormones to proliferate, which culminates in the development of metastases, leading to patient death.\(^{15}\)

**Apoptosis and disease**

Programmed cell death or apoptosis is an intrinsic cellular event of relevant importance in processes such as cell homeostasis, embryonic development and onset and maintenance of several diseases such as cancer and atherosclerosis.\(^{16,17}\) This mechanism develops through two pathways; the cell death receptor and the mitochondrial pathway.\(^{18}\) In turn, the apoptotic process develops in several stages: the first one is related to the stimuli that trigger programmed cell death, the second involves the signal transduction processes, in the third, effector enzymes that take care of cell disassembly, such as active caspases, participate and, finally, in the fourth, chromatin condensation, DNA degradation and apoptotic body formation occurs.\(^{16,19}\)

There are various apoptotic pathways, such as the extrinsic or death receptor pathway, whose initiating caspase is caspase 8, and the intrinsic or mitochondrial pathway, which has cytochrome C as intermediary protein and caspase 9 as initiator. Both can converge in the set of effector caspases, mainly caspases 3 and 7, which are activated through self-processing or cascade activation, whereby caspases themselves are self-activated and activated between each other.\(^{20,21}\) There is another alternative pathway called the perforin-granzyme pathway,\(^{22,23}\) which corresponds to an important serine protease complex in apoptosis that is induced by cytotoxic T cells by activating independent caspase pathways.

**Ca\(^{2+}\) as the second determining messenger in the apoptotic process**

Variations in intracellular Ca\(^{2+}\) concentration promote the onset of cellular events such as the regulation of metabolism, mitosis, secretion of neurotransmitters and hormones, as well as the contraction of myofilaments, and therefore it is considered a second messenger that is determinant for cell functions.\(^{24,25}\) Ca\(^{2+}\) levels are also involved in the regulatory mechanisms of apoptotic programmed cell death.\(^{26,27}\) A Ca\(^{2+}\) level higher than basal is considered highly toxic, since it generates the activation of proteases and phospholipases that participate in cell disassembly.\(^{28}\) The increase in Ca\(^{2+}\) can occur at early and late stages of apoptosis, through the outflow of Ca\(^{2+}\) from the endoplasmic reticulum and Ca\(^{2+}\) inflow to the cytoplasm through channels activated by Ca\(^{2+}\) release.\(^{7,29}\) It is necessary taking into account that part of intracellular Ca\(^{2+}\) moves to the endoplasmic
reticulum through the endoplasmic reticulum calcium pump and that Ca\textsuperscript{2+} is released from these stores by inositol 1,4,5 triphosphate receptors or ryanodine receptors. Additionally, in various intracellular organelles (such as the Golgi apparatus, nucleus and mitochondria) there are specialized systems for Ca\textsuperscript{2+} transport.

Calcium enters the cell through transmembrane proteins called calcium channels.\textsuperscript{31} Calcium passes through the channels by means of different mechanisms, depending on the type of channel or voltage, or through receptors; these pathways do not require energy, unlike calcium pumps, which release cytoplasmic calcium to the exterior of the cell at the expense of the use of adenosine triphosphate.

In collaboration with Dr. Agustín Guerrero of CINVESTAV, in the laboratory of the Institute of Cellular Physiology, National Autonomous University of Mexico, for the obtainment of electrophysiological records, the membrane fixation technique (patch clamp) and single cell simultaneous Ca\textsuperscript{2+} measurements were combined, with the purpose of studying the activation of Ca\textsuperscript{2+}-permeable channels using two different inducers: an ionophore (ionomycin) and serum elimination.\textsuperscript{8}
The latter deprives the cells from essential nutritional components such as proteins, growth factors and vitamins, inducing cells to death.\textsuperscript{32,33}

The results demonstrated the activation of a non-selective and Ca\textsuperscript{2+}-permeable cationic channel with 23pS-conductance. Ca\textsuperscript{2+} increased levels induced cells to apoptosis, which demonstrated that activation of this channel promotes the development of LN-CaP cells programmed death, which in turn constitutes an important finding for programmed death induction in this cell type (Fig. 1).

Continuing with this line of research, in our group, cDNA\textsc{arp2}, which codes for ARP2 of androgen-independent LN-CaP cells, and which were induced to apoptosis by serum removal, was isolated, identified and characterized.\textsuperscript{9} The sequence of this protein shows homology with the splicing factor prp8 (a component of the spliceosome)\textsuperscript{34} and proapoptotic functions in different cell types (Fig. 2). The alternative-type splicing mechanism is defined as a property that prevails in higher organisms to produce multiple proteins from a simple gene.\textsuperscript{35,36} Prp8 protein ubiquitin-binding activity suggests that some splicing factors for pre-mRNA can be ubiquitinated to have an interaction with Prp8.\textsuperscript{37}

\textit{Xenopus laevis} frog oocytes injected with \textsc{arp2} mRNA showed blistering after 12 hours of injection; these morphological changes were observed to increase when the oocytes are treated with thapsigargin (Fig. 3). It was also possible to observe that the
oocytes suffered a decrease in the resting membrane potential: from a control value of -46.8 ± 6.6 mV they went to -5.9 ± 3.4 mV (5-8 oocytes, two frogs) (Fig. 4). Incubation of the cells with thapsigargin accelerated and increased morphological changes, with the loss of definition of the animal and plant poles being evident, which was observed 36 hours after injection with arp2 mRNA and eight hours after incubation with thapsigargin (Figure 3B).

The morphological changes and membrane depolarization observed in our study have been described in *Xenopus laevis* oocytes when injected with cytochrome C to trigger the apoptotic mechanism, as well as in oocytes injected with the Bcl-xs proapoptotic molecule. Thapsigargin, a drug that depletes Ca\(^{2+}\) intracellular stores by the specific inhibition of endoplasmic reticulum Ca\(^{2+}\)-ATPase, elicits the activation of cytoplasmic membrane-independent voltage channels (TRP, transient receptor potential). 40

This way, we have gathered sufficient evidence that ARP2 is an apoptosis promoter in androgen-independent LNCaP cells and in Chinese hamster ovary epithelial cells, thus favoring Ca\(^{2+}\) sustained increases by directly interacting with Ca\(^{2+}\)-permeable membrane channels or by presenting a membrane channel function. On the other hand, considering the homology of the cDNA sequence that encodes ARP2 with the Prp8 splicing factor, it is not yet known whether this protein could additionally have any participation in the assembly or functioning of the spliceosome or be related to alternative splicing regulation mechanisms of mRNAs that encode proteins of the apoptotic machinery. There is a study where the Prp8 protein was observed to bind to one of the androgen receptor domains of prostate cancer cells and that, consequently, could be intervening in its functionality during the development of the disease. Furthermore, some splicing factors that make up the spliceosome, such as the SNW1 factor, have been reported to be linked to the development of breast cancer.

Continuing with the project, ARP2-encoding cDNA was cloned in an expression plasmid and transfected to androgen-independent LNCaP cells and Chinese hamster ovary cells. ARP2 overexpression induced the cells to develop apoptosis, with an important impact on cell viability and effector caspases 3 and 7.

![Figure 5. Confocal microscopy of the ARP2 fusion protein expressed in Chinese hamster ovary (CHO) cells. CHO cells transfected with egfp cDNA were observed at 24 hours post-transfection. A: Differential interference contrast microscopy; B: CHO cells transfected with arp2-egfp cDNA were also observed 24 hours post-transfection; C: Differential interference contrast microscopy; D: Bar scale: 50 µm. White arrows indicate that ARP2 is localized in the perinuclear region. Right side: CHO cells transfected with arp2-egfp cDNA examined at 16, 24, 48 and 72 hours post-transfection (A, C, E and G, respectively); same as above, but with differential interference contrast microscopy (B, D, F and H, respectively). Bar scale: 10 µm. Taken from reference 41.](image-url)
activation, which are comparable results to those of starving cells treated with ionomycin\(^\text{41}\) (Fig. 5). In this study, using confocal microscopy, it was possible to demonstrate that ARP2 is initially located in the perinuclear region of cells and migrates over time to the plasma membrane\(^\text{41}\) (Fig. 5). Taking into account our results, we consider that ARP2 is inserted into the plasma membrane, with a function similar to that of a membrane channel, thus constituting a valuable target to modulate Ca\(^{2+}\) flow and concentration in the cytoplasm of epithelial cancer cells that show an apoptosis-resistant phenotype\(^\text{41}\) (Fig. 6).

**Perspectives**

The apoptosis mechanism in malignant cell resistant phenotypes has been the subject of extensive study in recent years. Due to the strong impact of cancer development, implementation of successful molecular strategies that support treatments against this disease is urgent. Our group has demonstrated that ARP2 protein overexpression induces programmed cell death in different cell types: androgen-independent lymphoid nodule prostate cancer cells, from where it was originally isolated, Chinese hamster ovary cells, embryonic human kidney cells and coronary artery endothelial cells (data not shown).

Given the collected experimental evidence, we consider that ARP2 could be contributing during its overexpression to the increase in Ca\(^{2+}\) intracellular levels as a messenger molecule or as a protein inserted in the membrane that favors Ca\(^{2+}\) inflow. In addition to being found in the membrane region, we also observed its perinuclear localization, and due to the homology with the Prp8 factor, there is the possibility that it participates in the alternative splicing mechanisms of pro-apoptotic molecules.\(^\text{44-46}\) In this sense, and taking into account that transcription through alternative splicing mechanisms are molecular processes that are highly regulated by Ca\(^{2+}\) intracellular level, among other factors,\(^\text{47,48}\) it is feasible to think that ARP2 might have a double function: in the control of plasma Ca\(^{2+}\) flow and in alternative splicing molecular mechanisms.

Based on the evidence that cell death genes are deregulated in cancer, a phenomenon that is associated with the control of their alternative splicing patterns, it is reasonable thinking that the apoptosis process
occurs as a positive response to chemotherapy.\textsuperscript{19} If we take into account that anticancer drugs efficacy may also depend on apoptosis activation or on a form of cell-senescence acute induction, we consider that ARP2 protein overexpression could potentially be used as a new tool in the treatment epithelial-type cancer.

References

1. Veneis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014;383:549-557.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Hossein-Hassanpour S, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4:127-129.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
5. Schottenfeld D, Fraumeni JF. Cancer epidemiology and prevention. In:gateira: Oxford Scholarship Online; 2006.
6. Yoo KY. Shin HR. Cancer epidemiology and prevention. Korean J Epidemiol. 2003;25:1-15.
7. Pintor F, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis. ER-mitochondria Ca\textsuperscript{2+} transfer in the control of apoptosis. Oncogene. 2008;27:6407-6418.
8. Gutiérrez AA, Arias JM, García L, Mas-Oliva J, Guerrero-Hernández A. Activation of a Ca\textsuperscript{2+} permeable cation channel by two different inducers of apoptosis in a human prostate cancer cell line. J Physiol. 1999;15:95-107.
9. Tapia-Vieyra JV, Arelanno RD, Mas-Oliva J. ARP2, a novel protein involved in apoptosis of LNCaP cells shares a high degree homology with splicing factor Prp8. Mol Cell Biochem. 2005;269:189-201.
10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
11. Dall’Era MA, Albertsen PC, Bangma C, Carroll HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976-983.
12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
13. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224.
14. Talcott JA in the clinic. Prostate cancer. Ann Intern Med. 2015;163:ITC1-ITC12.
15. Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017;28:2658-2669.
16. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
17. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and cancer: a resemblance with far-reaching implications. Arch Med Res. 2017;48:12-26.
18. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7:313-319.
19. Cooper KF. Till death do us part: the marriage of autophagy and apoptosis. Oxidative Med Cell Longevity. 2018;1:1-13.
20. Fults S, Debath KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798-4811.
21. Hassan M, Watarai H, Abukimy AA, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845.
22. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.
23. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003;17:2481-2495.
24. Mason RP. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J Am Coll Cardiol. 1999;34:1857-1866.
25. Clapham DE. Calcium signaling. Cell. 2007;131:1047-1058.
26. Rizzuto R, Pintor F, Ferrari D, Chami M, Szabadiak G, Magaíales PJ, et al. Calcium and apoptosis: facts and hypotheses. Oncogene. 2003;22:8619-8627.
27. Giorgi C, Romagnoli A, Pintor F, Rizzuto R. Ca\textsuperscript{2+} signaling, mitochondria and cell death. Curr Mol Med. 2008;8:119-130.
28. Fanis MW, Pascoe GA, Reed DJ. Vitamin E reversal of the effect of extracellular calcium on chemically induced toxicity in hepatocytes. Science. 1985;227:751-754.
29. Pintor F, Rizzuto R. Bcl-2 and Ca\textsuperscript{2+} homeostasis in the endoplasmic reticulum. Cell Death Differ. 2006;13:1409-1418.
30. Górlach A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: a mutual interplay. Redox Biol. 2015;3:260-271.
31. Tapia-Vieyra JV, Mas-Oliva J. Apoptosis and cell death channels in prostate cancer. Arch Med Res. 2001;32:175-185.
32. Schramberger CJ, Gerner C, Cerni C. Caspase-9 plays a marginal role in serum starvation-induced apoptosis. Exp Cell Res. 2005;302:115-128.
33. Braun F, Berth-Côtéo J, Gallouet AS, Milour J, Juin P. Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counte - racted by p21 and unmasked by Bcl-xL inhibition. PlosOne. 2011;6:e23077.
34. Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Faitheree M, et al. Function of alternative splicing. Gene. 2017;514:1-30.
35. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 2003;72:291-338.
36. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell. 2006;126:37-47.
37. Bellare P, Kutach AK, Rines AK, Guthrie C, Sontheimer EJ. Ubiquitin binding by a variant fab1/PM domain in the essential pre-mRNA splicing factor Prp8. RNA. 2005;11:1940-1952.
38. Bhuyan AK, Varshney A, Mathew MK. Resting membrane potential as a marker of apoptosis: studies of xenopus oocytes microinjected with cyt ochrome c. Cell Death Differ. 2001;1:63-89.
39. Braun T, Dar S, Voroibiov D, Lindenboim L, Dascal N, Stein R. 2003. Expression of Bcl-x(S) in xenopus oocytes induces Bcl3-dependent and caspase-dependent cytochrome c release and apoptosis. Mol Cancer Res. 2003;1:186-194.
40. Bouläs G, Zhu X, Peyton M, Jiang M, Hurst R, Enrico S, et al. Cloning and expression of a novel mammalian homolog of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the G\textsubscript{12} class of G protein. J Biol Chem. 1997;272:29672-29680.
41. Mas-Oliva J, Navarro-Vidal E, Tapia-Vieyra JV. ARPA, a novel pro-apop - totic protein expressed in epithelial prostate cancer LNCaP cells and epithelial ovari CHO transformed cells. Plos One. 2014;9:e86089.
42. Wang D, Nguyen MM, Masoodi KZ, Singh P, Jing Y, O’Malley K, et al. Splicing factor Prp8 interacts with NES(AR) and regulates androgen receptor in prostate cancer cells. Mol Endocrinol. 2015;29:1731-1742.
43. Sato N, Maeda M, Sugiyama M, Ito S, Hyodo T, Masuda A, et al. Inhibition of SNW1 association with spliceosomal proteins promotes apoptosis in breast cancer cells. Cancer Med. 2015;4:268-277.
44. Maniatis T, Tasic B. Alternative pre-mRNA splicing and proteome expan - sion in metazoans. Nature. 2002;418:236-243.
45. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell. 2005;19:1-13.
46. Moore MJ, Wang G, Kennedy CJ, Silver PA. An alternative splicing ne - twork links cell-cycle control to apoptosis. Cell. 2010;142:625-636.
47. Krebs J. The influence of calcium signaling on the regulation of alternati - ve splicing. Biochim Biophys Acta. 2005;1739:951-955.
48. Tarn WY. Cellular signals modulate alternative splicing. J Biol Chem. 2007;14:517-522.
49. Bracco L, Kearsy J. The relevance of alternative RNA splicing to pharma - genomics. Trends Biotechnol. 2003;21:346-355.